MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $140.60M
Last updated: Nov 17, 2026 at 11:06 AM ET
MacroGenics Inc (MGNX) Financials: Revenue, Profit and Cash Flow
MacroGenics reported revenue of $149.50M for the fiscal year ended Dec 31, 2025, down 0.3% from the year before. That year, net income was -$74.62M with a net margin of -49.9%, operating cash flow was -$81.04M and free cash flow was -$82.95M. The quarter ended Sep 30, 2026 had revenue of $18.67M and net income of -$20.08M.
Revenue and Margins
The operating margin was -48.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $91.88M, a compound annual rate of 5.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $149.50M | -0.3% | 100.0% | -48.7% | -49.9% |
| Dec 2024 | $149.96M | +155.3% | 99.4% | -73.7% | -44.7% |
| Dec 2023 | $58.75M | -61.3% | 98.9% | -286.4% | -15.4% |
| Dec 2022 | $151.94M | +96.2% | 97.8% | -79.9% | -78.8% |
| Dec 2021 | $77.45M | -26.2% | 96.6% | -261.9% | -261.0% |
| Dec 2020 | $104.88M | +63.4% | 100.0% | -125.0% | -123.7% |
| Dec 2019 | $64.19M | +6.8% | 100.0% | -276.0% | -236.5% |
| Dec 2018 | $60.12M | -61.9% | 100.0% | -284.8% | -285.2% |
| Dec 2017 | $157.74M | +71.7% | 100.0% | -14.0% | -12.4% |
| Dec 2016 | $91.88M | N/A | 100.0% | -65.3% | -63.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $149.50M | $149.96M | $58.75M | $151.94M | $77.45M | $104.88M | $64.19M | $60.12M | $157.74M | $91.88M |
| Cost of revenue | $0 | $847.00K | $619.00K | $3.35M | $2.65M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $149.50M | $149.12M | $58.13M | $148.59M | $74.80M | $104.88M | $64.19M | $60.12M | $157.74M | $91.88M |
| Research and development | $147.17M | $177.19M | $166.58M | $207.03M | $214.58M | $193.20M | $195.31M | $190.83M | $147.23M | $122.09M |
| Operating income | -$72.84M | -$110.58M | -$168.24M | -$121.42M | -$202.79M | -$131.06M | -$177.19M | -$171.21M | -$22.14M | -$60.04M |
| Net income | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -$202.12M | -$129.74M | -$151.81M | -$171.45M | -$19.63M | -$58.53M |
| EBITDA | -$61.26M | -$96.43M | -$153.92M | -$107.49M | -$189.93M | -$119.36M | -$166.34M | -$162.93M | -$14.91M | -$52.43M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.67M | $32.83M | $20.77M | $41.23M | $53.00M | $6.87M | $13.19M | $19.35M | $110.71M | $10.80M | $9.10M | $10.72M |
| Gross profit | $18.67M | $32.83M | $20.77M | $41.23M | $53.00M | $6.87M | $13.19M | $19.12M | $110.54M | $10.62M | $8.83M | $10.56M |
| Operating income | -$20.30M | -$13.85M | -$33.44M | -$12.10M | $10.39M | -$43.22M | -$42.62M | -$52.84M | $54.19M | -$58.18M | -$53.75M | -$49.35M |
| Net income | -$20.08M | $19.52M | -$36.77M | -$14.15M | $16.82M | -$36.25M | -$41.04M | -$15.42M | $56.31M | -$55.66M | -$52.19M | -$46.07M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $5.18M by $52.04M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $256.85M | $261.65M | $298.42M | $280.47M | $335.25M | $378.74M | $312.50M | $332.13M | $373.88M | $311.26M |
| Current assets | $219.94M | $217.49M | $251.34M | $222.18M | $279.56M | $312.59M | $239.78M | $269.12M | $322.30M | $283.95M |
| Cash and equivalents | $57.22M | $182.84M | $100.96M | $108.88M | $123.47M | $181.13M | $126.47M | $220.13M | $211.73M | $84.10M |
| Total liabilities | $201.25M | $145.60M | $145.81M | $138.46M | $95.63M | $82.86M | $81.87M | $89.25M | $74.64M | $42.51M |
| Short-term debt | $5.18M | $4.86M | $3.77M | $4.73M | $4.68M | $3.99M | $3.02M | $34.04M | $298.00K | $1.59M |
| Shareholder equity | $55.59M | $116.06M | $152.61M | $142.01M | $239.62M | $295.88M | $230.63M | $242.88M | $299.24M | $268.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $318.69M | $345.41M | $217.87M | $256.85M | $270.76M | $245.42M | $224.56M | $261.65M | $264.49M | $201.14M | $248.28M | $298.42M |
| Total liabilities | $293.53M | $302.54M | $196.68M | $201.25M | $203.76M | $198.80M | $145.45M | $145.60M | $144.43M | $143.32M | $142.13M | $145.81M |
| Cash and equivalents | $49.03M | $113.91M | $66.52M | $57.22M | $80.13M | $130.69M | $145.57M | $182.84M | $179.63M | $83.93M | $80.36M | $100.96M |
| Shareholder equity | $25.15M | $42.87M | $21.20M | $55.59M | $67.00M | $46.62M | $79.12M | $116.06M | $120.07M | $57.82M | $106.15M | $152.61M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$81.04M | -$68.37M | -$78.20M | -$86.96M | -$143.83M | -$111.90M | -$134.27M | -$153.23M | $14.40M | -$43.68M |
| Capital expenditures | $1.91M | $3.71M | $1.76M | $3.62M | $6.20M | $5.91M | $4.29M | $24.95M | $29.40M | $11.38M |
| Free cash flow | -$82.95M | -$72.08M | -$79.97M | -$90.58M | -$150.03M | -$117.80M | -$138.56M | -$178.19M | -$15.00M | -$55.06M |
| Investing cash flow | -$114.10M | $149.30M | -$80.08M | $70.72M | -$36.61M | -$7.79M | -$79.36M | $56.64M | $77.88M | -$70.25M |
| Financing cash flow | $69.51M | $960.00K | $150.36M | $1.66M | $122.78M | $174.34M | $119.97M | $104.99M | $35.35M | $1.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.33M | -$40.75M | -$35.81M | $43.02M | -$30.19M | -$46.98M | -$46.89M | -$38.41M | $60.16M | -$44.48M | -$45.64M | -$28.04M |
| Capital expenditures | $72.00K | $806.00K | $344.00K | $244.00K | $426.00K | $715.00K | $529.00K | $620.00K | $592.00K | $1.03M | $1.46M | $620.00K |
| Free cash flow | -$6.40M | -$41.55M | -$36.16M | $42.78M | -$30.61M | -$47.70M | -$47.42M | -$39.03M | $59.57M | -$45.52M | -$47.10M | -$28.66M |
Frequently Asked Questions About MGNX
What is MacroGenics' annual revenue?
MacroGenics reported revenue of $149.50M for the fiscal year ended Dec 31, 2025.
How fast is MacroGenics' revenue growing?
Revenue was down 0.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.5%.
Is MacroGenics profitable?
No. MacroGenics reported net income of -$74.62M for the fiscal year ended Dec 31, 2025, with a net margin of -49.9%.
How much free cash flow does MGNX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$81.04M minus capital expenditures of $1.91M produced free cash flow of -$82.95M.
How much debt does MacroGenics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.18M and cash and equivalents of $57.22M.
MGNX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts